ZYRTEC® Clinical Data
ZYRTEC® significantly improved quality of life (QoL) in adult SAR patients*1-3
Patients receiving ZYRTEC® reported significantly greater improvements in overall RQLQ scores compared with placebo
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a validated measurement of overall QoL. These studies used the 28-item RQLQ, which measured 7 domains: activity limitation, sleep problems, nose symptoms, eye symptoms, non–hay fever symptoms, practical problems, and emotional function.†
Download the PDF to view the PAR data and more.
*Two multicenter, randomized, double-blind, placebo-controlled studies including 1254 adult SAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.
†Adult RQLQ assessed domains on a 7-point (0-6) rating scale.4
‡Endpoint = last post-baseline observation.
References: 1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Health Division. 2. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):391-398. 3. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCI in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;3(3):351-358. 4. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjuntivitis. Clin Exp Allergy. 1991;21(1):77-83.
Need samples or patient resources?
More clinical data on ZYRTEC®
Here are additional clinical data on the efficacy and tolerability of ZYRTEC®
ZYRTEC® products
See the complete family of ZYRTEC® products.
